This Article Full Text Full Text (PDF) CME: Take the course for this article: Intermittent Androgen Deprivation Therapy for Prostate Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rashid, M. H. Articles by Chaudhary, U. B. Search for Related Content PubMed PubMed Citation Articles by Rashid, M. H. Articles by Chaudhary, U. B.

Intermittent Androgen Deprivation Therapy for Prostate Cancer

Department of Medicine, Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA

Correspondence: Uzair B. Chaudhary, M.D., Medical University of South Carolina, Division of Hematology/Oncology, 96 Jonathan Lucas Street, 903 CSB, P.O. Box 250623, Charleston, South Carolina 29425, USA. Telephone: 843-792-4271; Fax: 843-792-0644; e-mail: chaudu{at}musc.edu

Androgen deprivation therapy for prostate cancer is associated with several complications, including loss of libido, hot flashes, night sweats, psychological stress, osteoporosis, anemia, fatigue, loss of muscle mass, glucose intolerance, and changes in lipid profile. The natural history of prostate cancer while on such therapy is the attainment of an incurable androgen-independent state. Early diagnosis by prostate-specific antigen screening, longer life expectancies, and a penchant for immediate therapy pose a problem where clinicians have to balance the potential benefits of early hormonal therapy with the risks of development of these metabolic and psychological complications. Intermittent androgen deprivation offers clinicians a prospect to improve quality of life in patients with prostate cancer by harmonizing the benefits of androgen ablation with a reduction in treatment-related side effects and expenditure. In this review we discuss the challenges and opportunities of this mode of therapy and shed light on some of the underlying molecular mechanisms.

Key Words. Prostate cancer • Intermittent androgen deprivation • Hormonal therapy

This article has been cited by other articles:

				D. Feltquate, L. Nordquist, C. Eicher, M. Morris, O. Smaletz, S. Slovin, T. Curley, A. Wilton, M. Fleisher, G. Heller, et al. Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7414 - 7421. [Abstract] [Full Text] [PDF]

				T. Nishiyama, F. Ishizaki, T. Anraku, H. Shimura, and K. Takahashi The Influence of Androgen Deprivation Therapy on Metabolism in Patients with Prostate Cancer J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 657 - 660. [Abstract] [Full Text] [PDF]